CardiNor Leads The Charge As Norway Gets Behind Life Sciences
Executive Summary
Norwegian start-up CardiNor is developing a new cardiovascular biomarker, and is hopeful of attracting cash in a country where investor traditions are undergoing some changes. The financial pressures caused by falling oil prices have brought renewed attention to life science companies.
You may also be interested in...
Start-Up Quarterly Statistics, Q1 2016
Start-ups raised $1.8 billion in Q1 2016. Biopharma companies penned 33 alliances; 14 acquisitions were signed (11 in the biopharma industry).
Algeta, Aspiring For Solo Success, Draws Bayer Bid After Xofigo Launch
The Norwegian biotech is keen to show it is not a one-trick pony, but its future might lie in the embrace of its big pharma partner Bayer.
Biosecurity Centre And ‘Test And Trace’ To Augment UK’s COVID-19 Test Momentum
The UK has added important new capabilities to its COVID-19 monitoring and control effort and those running it promise a “world class system” by late summer.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports